Phase Ib trial of bryostatin 1 in patients with refractory malignancies

Clinical Cancer Research

Volumn 4, Issue 3, 1998, Pages 611-618

  Grant, Steven ^a,b   Roberts, John ^a   Poplin, Elizabeth ^a   Tombes, Mary Beth ^a   Kyle, Brenda ^a   Welch, Dawn ^b   Carr, Marc ^a   Bear, Harry D ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRYOSTATIN; MACROLIDE; PROTEIN KINASE C ACTIVATOR;

ADULT; AGED; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FATIGUE; FEMALE; FEVER; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MELANOMA; MYALGIA; PANCREAS CANCER; PHLEBITIS; PRIORITY JOURNAL; PRURITUS; THROMBOCYTOPENIA;

EID: 0031954529     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Pettit, G. R., Herald, C. L., Doubek, D. L., Herald, D. L., Arnold, E., and Clardy, J. Isolation and structure of bryostatin 1. J. Am. Chem. Soc., 104: 6846-6948, 1982.
2. Hess, A. D., Silankis, M. K., Esa, A. H., Pettit, G. R., and May, W. S. Activation of human T lymphocytes by bryostatin 1. J. Immunol., 141: 3263-3269, 1988.
3. Kennedy, M. J., Prestigiacomo, L. J., Tyler, G., May, W. S., and Davidson, N. E. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines. Cancer Res., 52: 1278-1283, 1992.
4. Dale, I. L., and Gescher, A. Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int. J. Cancer, 43: 158-163, 1989.
5. Schuchter, L. M., Esa, A. H., May, S., Laulis, M. K., Pettit, G. R., and Hess, A. D. Successful treatment of murine melanoma with bryostatin 1. Cancer Res., 51: 682-687, 1991.
6. Hornung, R. L., Pearson, J. W., Beckwith, M., and Longo, D. L. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: in vitro versus in vivo activity. Cancer Res., 52: 101-107, 1992.
7. Jones, R. J., Sharkis, S. J., Miller, C. B., Rowinsky, E. K., Burke, P. J., and May, W. S. Bryostatin 1, a unique biologic response modifier: antileukemic activity in vitro. Blood, 75: 1319-1323, 1990.
8. May, W. S., Sharkis, S. S., Esa, A. H., Gebbia, V., Kraft, A. S., Pettit, G. R., and Sensenbrenner, L. L. Antineoplastic bryostatins are multipotent stimulators of human hematopoietic progenitor cells. Proc. Natl. Acad. Sci. USA, 84: 8483-8487, 1987.
9. Sharkis, S. J., Jones, R. J., Bellis, M. L., Demetri, G. D., Griffin, J. D., Civin, C., and May, W. S. The action of bryostatin 1 on normal human hematopoietic progenitors is mediated by accessory cell release of growth factors. Blood, 76: 716-721, 1990.
10. Philip, P. A., Rea, D., Thavasu, P., Carmichael, J., Stuart, N. S., Rockett, H., Talbot, D. C., Ganesan, T., Pettit, G. R., Balkwill, F., and Harris, A. L. Phase I study of bryostatin 1 : assessment of interleukin-6 and tumor necrosis factor α in vivo. J. Natl. Cancer Inst., 85: 1812-1818, 1993.
11. Prendiville, J., Crowther, D., Thatcher, N., Woll, P. J., Fox, B. W., McGown, A., Testa, N., Stern, P., McDermott, R., Potter, M., and Pettit, G. R. A Phase I study of intravenous bryostatin 1 in patients with advanced cancer. Br. J. Cancer, 68: 418-424, 1993.
12. Jayson, G. C., Crowther, D., Prendiville, J., McGown, A. T., Scheid, C., Stern, P., Young, R., Brenchley, P., Chang, J., Owens, S., and Pettit, G. R. A Phase I trial of bryostatin 1 in patients with advanced malignancy using a 24-hour intravenous infusion. Br. J. Cancer, 72: 461-468, 1995.
13. Scheid, C., Prendiville, J., Jayson, G., Crowther, D., Fox, B., Pettit, G. R., and Stern, P. L. Immunomodulation in patients receiving bryostatin 1 in a Phase I clinical study: comparison with effects of bryostatin 1 on lymphocyte function in vitro. Cancer Immunol. Immunother., 39: 223-230, 1994.
14. Berkow, R. L., and Kraft, A. S. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Biochem. Biophys. Res. Commun., 131: 1109-1116, 1985.
15. Kraft, A. S., Smith, J. B., and Berkow, R. L. Bryostatin, an activator of the calcium phospholipid-dependent protein kinase, blocks phorbol ester-induced differentiation of human promyelocytic leukemia cells HL-60. Proc. Natl. Acad. Sci. USA, 83: 1334-1338, 1986.
16. Hennings, H., Blumberg, P. M., Pettit, G. R., Herald, C. L., Shores, R. A., and Yuspa, S. H. Bryostatin 1, an activator of protein kinase C, inhibits tumor promotion by phorbol esters in SENCAR mouse skin. Carcinogenesis (Lond.), 8: 1343-1346, 1987.
17. Ng, S. B., and Guy, G. R. Two protein kinase activators, bryostatin I and phorbol-12-myristate-13-acetate, have different effects on haemopoietic cell proliferation and differentiation. Cell Signalling, 4: 405-416, 1992.
18. Szallasi, Z., Smith, C. B., Pettit, G. R., and Blumberg, P. M. Differential regulation of protein kinase C isozymes by bryostatin 1 and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts. J. Biol. Chem., 269: 2118-2124, 1994.
19. II-protein kinase C to the nucleus of human promyelocytic (HL-60) leukemia cells. J. Biol. Chem., 266: 28-33, 1991.
20. Isakov, N., Galron, D., Mustelin, T., Pettit, G. R., and Altman, A. Inhibition of phorbol ester-induced T cell proliferation by bryostatin 1 is associated with rapid degradation of protein kinase C. J. Immunol., 150: 1195-1204, 1993.
21. Lee, H-W., Smith, L., Pettit, G. R., Vinitsky, A., and Smith, J. B. Ubiquitination of protein kinase C-α and degradation by the proteosome. J. Biol. Chem., 271: 20973-20976, 1996.
22. 2+-sensitive, phospholipid-dependent kinase activity in phorbol ester-treated 3T3 cells. Biochem. Biophys. Res. Commun., 120: 1053-1059, 1984.
23. Grant, S., Jarvis, D., Swerdlow, P., Turner, A., Traylor, R., Wallace, H., Lin, P-S., Pettit, G. R., and Gewirtz, D. A. Potentiation of the activity of 1-β-D-arabinofuranosylcytosine by the macrocyclic lactone PKC activator bryostatin 1 in HL-60 cells: association with enhanced fragmentation of mature DNA. Cancer Res., 52: 6270-6278, 1992.
24. Jarvis, W. D., Gewirtz, D. A., Povirk, L., Turner, A., Traylor, R., Pettit, G. R., and Grant, S. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-β-D-arabinofuranosylcytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells. Biochem. Pharmacol., 47: 839-852, 1994.
25. Lotem, J., Cragoe, E. J., and Sachs, L. Rescue from programmed cell death in leukemia and normal myeloid cells. Blood, 78: 953-960, 1991.
26. McConkey, D. J., Hartzell, P., Jondal, M., and Orrenius, S. Inhibition of DNA fragmentation in thymocytes and isolated thymocyte nuclei by agents that stimulate protein kinase C. J. Biol. Chem., 264: 13399-13402, 1989.
27. Bertrand, R., Solary, E., O'Connor, P., Kohn, K. W., and Pommier, Y. Induction of a common pathway of apoptosis by staurosporine. Exp. Cell Res., 211: 314-321, 1994.
28. Grant, S., Turner, A., Bartimole, T. M., Nelms, P. A., Joe, V. C., and Jarvis, W. D. Modulation of 1-β-D-arabinofuranosylcytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C. Oncol. Res., 6: 87-99, 1994.
29. Kauffman, S. H. Induction of endonucleolytic DNA cleavage by in human acute myelogenous leukemia cells by etoposide, camptothecin, and other cytotoxic anticancer agents: a cautionary note. Cancer Res., 49: 5870-5878, 1989.
30. Gorczyca, W., Bigman, K., Mittelman, A., Ahmed, T., Gong, J., Melamed, M. R., and Darzynkiewicz, Z. Induction of DNA strand breaks associated with apoptosis during treatment of leukemias. Leukemia (Baltimore), 7: 659-670, 1993.
31. Bear, H. D., McFadden, A., Turner, A. J., and Grant, S. Bryostatin 1 induces long-term depletion of protein kinase C in vivo following a single intravenous injection. Anticancer Res., 6: 384-391, 1995.
32. Boyum, A. Isolation of mononuclear cells and granulocytes from human blood. Scand. J. Clin. Lab. Invest., 21: 77-84, 1968.
33. Grant, S., Turner, A. J., Freemerman, A. J., Wang, Z., Kramer, L., and Jarvis, W. D. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: relationship to differentiation and ara-C-induced apoptosis. Exp. Cell Res., 228: 65-75, 1996.
34. Carr, M. E., Jr., Carr, S. L., and Grant, S. A sensitive platelet activation-based functional assay for the antileukemic agent bryostatin 1. Anticancer Drugs, 6: 384-391, 1995.
35. Bear, H. D., Susskind, B. M., Close, K. A., and Barrett, S. K. Phenotype of tumor-specific cytotoxic T-lymphocytes and requirements for their in vitro generation from tumor-bearing host and immune spleens. Cancer Res., 48: 1422-1427, 1988.
36. + cytotoxic T lymphocytes via CD3-ε differs from triggering via α/β T cell receptor: CD3-ε-induced cytotoxicity occurs in the absence of protein kinase C and does not result in exocytosis of serine esterases. J. Immunol., 147: 1115-1120, 1991.
37. Conrad, D. H. Feε RII/CD23. The low affinity receptor for for IgE. Annu. Rev. Immunol., 8: 623-645, 1990.
38. Grant, S., Traylor, R., Bhalla, K., McCrady, C., and Pettit, G. R. Effect of a combined exposure to 1-β-D-arabinofuranosylcytosine, bryostatin 1, and rGM-CSF on the in vitro clonogenic growth of normal and leukemic human hematopoietic progenitor cells. Leukemia (Baltimore), 5: 432-439, 1993.
39. Mohammad, R. M., Al-Katib, A., Pettit, G. R., and Sensenbrenner, L. L. Successful treatment of human Waldenstrom's macroglobulinemia with combination biological and chemotherapy agents. Cancer Res., 54: 165-168, 1994.
40. Szallasi, Z., Du, L., Levine, R., Lewin, N. E., Nguyen, P. N., Williams, M. D., Pettit, G. R., and Blumberg, P. M. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro though a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1. Cancer Res., 56: 2105-2111, 1996.
41. Varterasian, M., Eilender, D., Mohammad, R., Chen, B., Hulburd, K., Rodriguez, D., Pluda, J., Valdivieso, M., and Al-Katib, A. Phase I trial of bryostatin 1 in relapsed lymphoma and CLL. Proc. Am. Soc. Clin. Oncol., 15: 481, 1996.
42. Hannun, Y. A. Functions of ceramide in coordinating cellular responses to stress. Science (Washington DC), 274: 1855-1859, 1996.
43. Cuvillier, O., Pirianov, G., Kleuser, B., Vanek, P. G., Coso, O. A., Gutkind, J. S., and Spiegel, S. Suppression of ceramide-mediated programmed cell death by sphingosine-1-phosphate. Nature (Lond.), 381: 800-803, 1996.
44. Grant, S., and Jarvis, W. D. Modulation of drug-induced apoptosis by interruption of the protein kinase C signal transduction pathway: a new therapeutic strategy. Clin. Cancer Res., 2: 1915-1920, 1996.
45. Berkow, R. L., Schlabach, L., Dodson, R., Benjamin, W. H., Jr., Pettit, G. R., Rustagi, P., and Kraft, A. S. In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity. Cancer Res., 53: 2810-2815. 1993.
46. Zhang, X., Zhang, R., Zhao, H., Cai, H., Gush, K. A., Kerr, R. G., Pettit, G. R., and Kraft, A. S. Preclinical pharmacology of the natural product anticancer agent bryostatin 1, an activator of protein kinase C. Cancer Res., 56: 802-808, 1996.
47. Kraft, A. S., Adler, V., Hall, P., Pettit, G. R., Benjamin, W. H., and Briles, D. E. In vivo administration of bryostatin 1, a protein kinase C activator, decreases murine resistance to Salmonella typhimurium. Cancer Res., 52: 2143-2147, 1992.